Susquehanna International Group LLP Buys 172,828 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)

Susquehanna International Group LLP lifted its position in Alpha Teknova, Inc. (NASDAQ:TKNO - Free Report) by 472.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 209,409 shares of the company's stock after acquiring an additional 172,828 shares during the quarter. Susquehanna International Group LLP owned 0.39% of Alpha Teknova worth $1,749,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Nkcfo LLC bought a new position in shares of Alpha Teknova in the fourth quarter worth about $501,000. Invesco Ltd. purchased a new stake in Alpha Teknova in the 4th quarter valued at about $9,236,000. Raymond James Financial Inc. bought a new position in Alpha Teknova in the 4th quarter worth about $716,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Alpha Teknova during the fourth quarter worth approximately $94,000. Finally, Mount Lucas Management LP bought a new stake in shares of Alpha Teknova during the fourth quarter valued at approximately $75,000. 13.81% of the stock is owned by hedge funds and other institutional investors.

Alpha Teknova Stock Down 3.3%

Shares of Alpha Teknova stock traded down $0.22 during trading on Wednesday, hitting $6.52. 356,675 shares of the stock traded hands, compared to its average volume of 382,999. The company has a current ratio of 4.73, a quick ratio of 3.94 and a debt-to-equity ratio of 0.12. The stock's fifty day simple moving average is $5.80 and its 200 day simple moving average is $7.11. The firm has a market cap of $348.44 million, a P/E ratio of -8.81 and a beta of 0.50. Alpha Teknova, Inc. has a 52-week low of $1.16 and a 52-week high of $10.37.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. The business had revenue of $9.60 million for the quarter, compared to the consensus estimate of $9.41 million. On average, equities analysts predict that Alpha Teknova, Inc. will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on Alpha Teknova in a research note on Monday, February 10th. They issued a "buy" rating and a $12.00 price objective on the stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.